iBio Inc., developer of the iBioLaunch platform technology for the development and production of biologics, today released interim results from its phase I clinical trial of a vaccine against Influenza A/California/04/09, better known as H1N1.
The vaccine was derived from the company’s iBioLaunch platform. The trial results show a strong immune response to the induction of the vaccine, which the company says demonstrates the platform’s ability to target deliver a flexible product offering.
“These expected positive results are an important confirmation of the utility of the iBioLaunch platform, not only for rapid response to infectious disease challenges such as influenza, but also as a preferred approach to a broad range of vaccine and therapeutic products,” Robert Kay, iBio’s chairman and CEO stated in the press release.
iBio’s research collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), sponsored the phase I trial. The vaccine was manufactured in the pilot plant at CMB’s Delaware facility.
The trial and relative assessments were conducted at the Walter Reed Army Institute of Research Clinical Trials Center, and an immunogenicity evaluation was conducted by the Influenza Division of the Centers for Disease Control and Prevention.
The company said it expects the final results of the study to be available by the end of the year.
For more information visit www.ibioinc.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment